Phase angle (PhA) in overweight and obesity: evidence of applicability from diagnosis to weight changes in obesity treatment
Phase angle (PhA) is a recently proposed marker of nutritional status in many clinical conditions. Its use in patients with obesity presents different critical concerns due to the higher variability of the two measured parameters (resistance, R, and reactance, Xc) that contribute to the determinatio...
Gespeichert in:
| Veröffentlicht in: | Reviews in endocrine & metabolic disorders 2023-06, Vol.24 (3), p.451-464 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 464 |
|---|---|
| container_issue | 3 |
| container_start_page | 451 |
| container_title | Reviews in endocrine & metabolic disorders |
| container_volume | 24 |
| creator | Cancello, Raffaella Brunani, Amelia Brenna, Ettore Soranna, Davide Bertoli, Simona Zambon, Antonella Lukaski, Henry C. Capodaglio, Paolo |
| description | Phase angle (PhA) is a recently proposed marker of nutritional status in many clinical conditions. Its use in patients with obesity presents different critical concerns due to the higher variability of the two measured parameters (resistance, R, and reactance, Xc) that contribute to the determination of PhA. Controversial is the relation between PhA and BMI that might vary with graded levels of obesity due to the variation in fat and free fat mass. Obesity is frequently associated with metabolic, hepatic, cardiovascular and kidney diseases that introduce variations in PhA values, in relation to multimorbidity and severity degree of these diseases. It is reported that the improvement of clinical condition is associated with a positive change in PhA. Also, the treatment of obesity with weight loss might confirm this effect, but with different responses in relation to the type and duration of the intervention applied. In fact, the effect appears not only related to the percentage of weight loss but also the possible loss of free fat mass and the nutritional, metabolic and structural modifications that might follow each therapeutic approach to decrease body weight. We can conclude that the PhA could be used as marker of health status in patients with obesity supporting an appropriate weight loss intervention to monitor efficacy and fat free mass preservation. |
| doi_str_mv | 10.1007/s11154-022-09774-1 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9735068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A747336187</galeid><sourcerecordid>A747336187</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-87ca448dde9a593644ed3aad0a0e22d1b976e4e8504e2c2deaec12fb12055ffa3</originalsourceid><addsrcrecordid>eNp9kk9rFTEUxQdRbK1-ARcScKOLqfmfiQvhUawKBbvQdcgkd2ZSZibPZN6Tgh_etPNsLYhkkZB7zi_3klNVLwk-JRird5kQIniNKa2xVorX5FF1TIRiNZVYPi5n1uhaEyGOqmc5X2FMidTiaXXEJG-45uy4-nU52AzIzv0I6M3lsHmLwoziHtJPCP2wlIpHsYUcluv3CPbBw-wAxQ7Z7XYMzrZhLCXUpTghH2w_xxwyWiI6-N1Q2JBvqSsGLQnsMsG8PK-edHbM8OKwn1Tfzz9-O_tcX3z99OVsc1E7wclSN8pZzhvvQVuhS-8cPLPWY4uBUk9arSRwaATmQB31YMER2rWEYiG6zrKT6sPK3e7aCbwrTyc7mm0Kk03XJtpgHlbmMJg-7o1WTGDZFMDrAyDFHzvIi7mKuzSXng1tsJSaa8nuVb0dwYS5iwXmppCd2SiuGJOkUUV1-g9VWR6m4OIMXSj3Dwx0NbgUc07Q3TVOsLkJglmDYEoQzG0QDCmmV3-PfGf58_NFwFZBLqXyQ-l-pP9gfwOPs8AI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2806694963</pqid></control><display><type>article</type><title>Phase angle (PhA) in overweight and obesity: evidence of applicability from diagnosis to weight changes in obesity treatment</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Cancello, Raffaella ; Brunani, Amelia ; Brenna, Ettore ; Soranna, Davide ; Bertoli, Simona ; Zambon, Antonella ; Lukaski, Henry C. ; Capodaglio, Paolo</creator><creatorcontrib>Cancello, Raffaella ; Brunani, Amelia ; Brenna, Ettore ; Soranna, Davide ; Bertoli, Simona ; Zambon, Antonella ; Lukaski, Henry C. ; Capodaglio, Paolo</creatorcontrib><description>Phase angle (PhA) is a recently proposed marker of nutritional status in many clinical conditions. Its use in patients with obesity presents different critical concerns due to the higher variability of the two measured parameters (resistance, R, and reactance, Xc) that contribute to the determination of PhA. Controversial is the relation between PhA and BMI that might vary with graded levels of obesity due to the variation in fat and free fat mass. Obesity is frequently associated with metabolic, hepatic, cardiovascular and kidney diseases that introduce variations in PhA values, in relation to multimorbidity and severity degree of these diseases. It is reported that the improvement of clinical condition is associated with a positive change in PhA. Also, the treatment of obesity with weight loss might confirm this effect, but with different responses in relation to the type and duration of the intervention applied. In fact, the effect appears not only related to the percentage of weight loss but also the possible loss of free fat mass and the nutritional, metabolic and structural modifications that might follow each therapeutic approach to decrease body weight. We can conclude that the PhA could be used as marker of health status in patients with obesity supporting an appropriate weight loss intervention to monitor efficacy and fat free mass preservation.</description><identifier>ISSN: 1389-9155</identifier><identifier>EISSN: 1573-2606</identifier><identifier>DOI: 10.1007/s11154-022-09774-1</identifier><identifier>PMID: 36484943</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Analysis ; Body Composition - physiology ; Body fat ; Body weight ; Body weight loss ; Diabetes ; Diagnosis ; Drug therapy ; Endocrinology ; Humans ; Internal Medicine ; Kidney diseases ; Liver diseases ; Medicine ; Medicine & Public Health ; Metabolism ; Nutritional Status ; Obesity ; Obesity - therapy ; Overweight ; Overweight - therapy ; Patients ; Type 2 diabetes ; Weight control ; Weight Loss</subject><ispartof>Reviews in endocrine & metabolic disorders, 2023-06, Vol.24 (3), p.451-464</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>COPYRIGHT 2023 Springer</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-87ca448dde9a593644ed3aad0a0e22d1b976e4e8504e2c2deaec12fb12055ffa3</citedby><cites>FETCH-LOGICAL-c541t-87ca448dde9a593644ed3aad0a0e22d1b976e4e8504e2c2deaec12fb12055ffa3</cites><orcidid>0000-0003-3059-544X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11154-022-09774-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11154-022-09774-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36484943$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cancello, Raffaella</creatorcontrib><creatorcontrib>Brunani, Amelia</creatorcontrib><creatorcontrib>Brenna, Ettore</creatorcontrib><creatorcontrib>Soranna, Davide</creatorcontrib><creatorcontrib>Bertoli, Simona</creatorcontrib><creatorcontrib>Zambon, Antonella</creatorcontrib><creatorcontrib>Lukaski, Henry C.</creatorcontrib><creatorcontrib>Capodaglio, Paolo</creatorcontrib><title>Phase angle (PhA) in overweight and obesity: evidence of applicability from diagnosis to weight changes in obesity treatment</title><title>Reviews in endocrine & metabolic disorders</title><addtitle>Rev Endocr Metab Disord</addtitle><addtitle>Rev Endocr Metab Disord</addtitle><description>Phase angle (PhA) is a recently proposed marker of nutritional status in many clinical conditions. Its use in patients with obesity presents different critical concerns due to the higher variability of the two measured parameters (resistance, R, and reactance, Xc) that contribute to the determination of PhA. Controversial is the relation between PhA and BMI that might vary with graded levels of obesity due to the variation in fat and free fat mass. Obesity is frequently associated with metabolic, hepatic, cardiovascular and kidney diseases that introduce variations in PhA values, in relation to multimorbidity and severity degree of these diseases. It is reported that the improvement of clinical condition is associated with a positive change in PhA. Also, the treatment of obesity with weight loss might confirm this effect, but with different responses in relation to the type and duration of the intervention applied. In fact, the effect appears not only related to the percentage of weight loss but also the possible loss of free fat mass and the nutritional, metabolic and structural modifications that might follow each therapeutic approach to decrease body weight. We can conclude that the PhA could be used as marker of health status in patients with obesity supporting an appropriate weight loss intervention to monitor efficacy and fat free mass preservation.</description><subject>Analysis</subject><subject>Body Composition - physiology</subject><subject>Body fat</subject><subject>Body weight</subject><subject>Body weight loss</subject><subject>Diabetes</subject><subject>Diagnosis</subject><subject>Drug therapy</subject><subject>Endocrinology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kidney diseases</subject><subject>Liver diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Nutritional Status</subject><subject>Obesity</subject><subject>Obesity - therapy</subject><subject>Overweight</subject><subject>Overweight - therapy</subject><subject>Patients</subject><subject>Type 2 diabetes</subject><subject>Weight control</subject><subject>Weight Loss</subject><issn>1389-9155</issn><issn>1573-2606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kk9rFTEUxQdRbK1-ARcScKOLqfmfiQvhUawKBbvQdcgkd2ZSZibPZN6Tgh_etPNsLYhkkZB7zi_3klNVLwk-JRird5kQIniNKa2xVorX5FF1TIRiNZVYPi5n1uhaEyGOqmc5X2FMidTiaXXEJG-45uy4-nU52AzIzv0I6M3lsHmLwoziHtJPCP2wlIpHsYUcluv3CPbBw-wAxQ7Z7XYMzrZhLCXUpTghH2w_xxwyWiI6-N1Q2JBvqSsGLQnsMsG8PK-edHbM8OKwn1Tfzz9-O_tcX3z99OVsc1E7wclSN8pZzhvvQVuhS-8cPLPWY4uBUk9arSRwaATmQB31YMER2rWEYiG6zrKT6sPK3e7aCbwrTyc7mm0Kk03XJtpgHlbmMJg-7o1WTGDZFMDrAyDFHzvIi7mKuzSXng1tsJSaa8nuVb0dwYS5iwXmppCd2SiuGJOkUUV1-g9VWR6m4OIMXSj3Dwx0NbgUc07Q3TVOsLkJglmDYEoQzG0QDCmmV3-PfGf58_NFwFZBLqXyQ-l-pP9gfwOPs8AI</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Cancello, Raffaella</creator><creator>Brunani, Amelia</creator><creator>Brenna, Ettore</creator><creator>Soranna, Davide</creator><creator>Bertoli, Simona</creator><creator>Zambon, Antonella</creator><creator>Lukaski, Henry C.</creator><creator>Capodaglio, Paolo</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3059-544X</orcidid></search><sort><creationdate>20230601</creationdate><title>Phase angle (PhA) in overweight and obesity: evidence of applicability from diagnosis to weight changes in obesity treatment</title><author>Cancello, Raffaella ; Brunani, Amelia ; Brenna, Ettore ; Soranna, Davide ; Bertoli, Simona ; Zambon, Antonella ; Lukaski, Henry C. ; Capodaglio, Paolo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-87ca448dde9a593644ed3aad0a0e22d1b976e4e8504e2c2deaec12fb12055ffa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Analysis</topic><topic>Body Composition - physiology</topic><topic>Body fat</topic><topic>Body weight</topic><topic>Body weight loss</topic><topic>Diabetes</topic><topic>Diagnosis</topic><topic>Drug therapy</topic><topic>Endocrinology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kidney diseases</topic><topic>Liver diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Nutritional Status</topic><topic>Obesity</topic><topic>Obesity - therapy</topic><topic>Overweight</topic><topic>Overweight - therapy</topic><topic>Patients</topic><topic>Type 2 diabetes</topic><topic>Weight control</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cancello, Raffaella</creatorcontrib><creatorcontrib>Brunani, Amelia</creatorcontrib><creatorcontrib>Brenna, Ettore</creatorcontrib><creatorcontrib>Soranna, Davide</creatorcontrib><creatorcontrib>Bertoli, Simona</creatorcontrib><creatorcontrib>Zambon, Antonella</creatorcontrib><creatorcontrib>Lukaski, Henry C.</creatorcontrib><creatorcontrib>Capodaglio, Paolo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Reviews in endocrine & metabolic disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cancello, Raffaella</au><au>Brunani, Amelia</au><au>Brenna, Ettore</au><au>Soranna, Davide</au><au>Bertoli, Simona</au><au>Zambon, Antonella</au><au>Lukaski, Henry C.</au><au>Capodaglio, Paolo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase angle (PhA) in overweight and obesity: evidence of applicability from diagnosis to weight changes in obesity treatment</atitle><jtitle>Reviews in endocrine & metabolic disorders</jtitle><stitle>Rev Endocr Metab Disord</stitle><addtitle>Rev Endocr Metab Disord</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>24</volume><issue>3</issue><spage>451</spage><epage>464</epage><pages>451-464</pages><issn>1389-9155</issn><eissn>1573-2606</eissn><abstract>Phase angle (PhA) is a recently proposed marker of nutritional status in many clinical conditions. Its use in patients with obesity presents different critical concerns due to the higher variability of the two measured parameters (resistance, R, and reactance, Xc) that contribute to the determination of PhA. Controversial is the relation between PhA and BMI that might vary with graded levels of obesity due to the variation in fat and free fat mass. Obesity is frequently associated with metabolic, hepatic, cardiovascular and kidney diseases that introduce variations in PhA values, in relation to multimorbidity and severity degree of these diseases. It is reported that the improvement of clinical condition is associated with a positive change in PhA. Also, the treatment of obesity with weight loss might confirm this effect, but with different responses in relation to the type and duration of the intervention applied. In fact, the effect appears not only related to the percentage of weight loss but also the possible loss of free fat mass and the nutritional, metabolic and structural modifications that might follow each therapeutic approach to decrease body weight. We can conclude that the PhA could be used as marker of health status in patients with obesity supporting an appropriate weight loss intervention to monitor efficacy and fat free mass preservation.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>36484943</pmid><doi>10.1007/s11154-022-09774-1</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-3059-544X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1389-9155 |
| ispartof | Reviews in endocrine & metabolic disorders, 2023-06, Vol.24 (3), p.451-464 |
| issn | 1389-9155 1573-2606 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9735068 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Analysis Body Composition - physiology Body fat Body weight Body weight loss Diabetes Diagnosis Drug therapy Endocrinology Humans Internal Medicine Kidney diseases Liver diseases Medicine Medicine & Public Health Metabolism Nutritional Status Obesity Obesity - therapy Overweight Overweight - therapy Patients Type 2 diabetes Weight control Weight Loss |
| title | Phase angle (PhA) in overweight and obesity: evidence of applicability from diagnosis to weight changes in obesity treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T10%3A53%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20angle%20(PhA)%20in%20overweight%20and%20obesity:%20evidence%20of%20applicability%20from%20diagnosis%20to%20weight%20changes%20in%20obesity%20treatment&rft.jtitle=Reviews%20in%20endocrine%20&%20metabolic%20disorders&rft.au=Cancello,%20Raffaella&rft.date=2023-06-01&rft.volume=24&rft.issue=3&rft.spage=451&rft.epage=464&rft.pages=451-464&rft.issn=1389-9155&rft.eissn=1573-2606&rft_id=info:doi/10.1007/s11154-022-09774-1&rft_dat=%3Cgale_pubme%3EA747336187%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2806694963&rft_id=info:pmid/36484943&rft_galeid=A747336187&rfr_iscdi=true |